SCHEMBL12876280

SCHEMBL12876280

CCOC(=O)c1cnn(Cc2nc(-c3cc(C)cc(C#C[Si](C)(C)C)c3)cs2)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 1/20 0.36
MAPK1 P28482 1/20 0.36
MAPT P10636 7/20 0.35
L3MBTL1 Q9Y468 5/20 0.35
KDM4E B2RXH2 5/20 0.35
HPGD P15428 4/20 0.35
GAA P10253 4/20 0.35
AKT1 P31749 1/20 0.35
CNKSR1 Q969H4 1/20 0.35
TP53 P04637 1/20 0.34
ALK Q9UM73 1/20 0.34
GABRA1 P14867 1/20 0.33
GABRG2 P18507 1/20 0.33
GABRB3 P28472 1/20 0.33
GABRA5 P31644 1/20 0.33
GABRA3 P34903 1/20 0.33
GABRA2 P47869 1/20 0.33
GABRA4 P48169 1/20 0.33
GABRA6 Q16445 1/20 0.33
ALDH1A1 P00352 6/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1199251 0.89 KDM4E (0.38) GRM2MAPK1MAPTL3MBTL1KDM4E
SCHEMBL12876283 0.89 GRM2 (0.38) GRM2MAPK1MAPTL3MBTL1KDM4E
SCHEMBL12875915 0.89 MAPK1 (0.44) GRM2MAPK1MAPTL3MBTL1KDM4E
SCHEMBL12876290 0.87 MAPK1 (0.38) GRM2MAPK1MAPTL3MBTL1KDM4E
SCHEMBL12876124 0.86 GRM5 (0.47) GRM2MAPK1MAPTL3MBTL1KDM4E
SCHEMBL12876288 0.85 MAPK1 (0.37) GRM2MAPK1MAPTL3MBTL1KDM4E
SCHEMBL12876118 0.85 GRM2 (0.40) GRM2MAPK1MAPTL3MBTL1KDM4E
SCHEMBL12876298 0.84 MAPK1 (0.36) GRM2MAPK1MAPTL3MBTL1KDM4E
SCHEMBL12875801 0.84 GRM2 (0.45) GRM2MAPK1MAPTL3MBTL1KDM4E
SCHEMBL12875909 0.84 GRM2 (0.39) GRM2MAPK1MAPTL3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A GRM2 1900/4885MAPK1 255/4885MAPT 4667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.